<DOC>
	<DOCNO>NCT01490775</DOCNO>
	<brief_summary>This study conduct population patient chronic phase Chronic Myeloid Leukemia ( CML ) learn patient follow prescribe regimen take oral cancer drug .</brief_summary>
	<brief_title>Pilot Study Assess Telemonitoring Gleevec ( Imatinib Mesylate ) Tasigna ( Niltinib ) Therapy</brief_title>
	<detailed_description>This randomize , control pilot study introduce eMedonline telemonitoring technology CML patient take Gleevec Tasigna . eMedonline use automatically collect time-dose specific medication data individual patient , include dose time , missed dos , adverse event e-diary data . All data available research staff remote review via Web interface . Adverse event non-adherence prompt intervention include supportive care counseling .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients 18 year age old . Pathologically documented diagnosis Chronic Phase CML ( Ph+ ) treat physician determine treatment imatinib nilotinib appropriate Patients currently receive Gleevec ( imatinib ) 300600 mg daily Tasigna ( nilotinib ) 300400 mg twice daily Known performance status 0,1 2 ( ECOG ) Known adequate end organ function , define : Total bilirubin &lt; 1.5 xULN SGOT SGPT &lt; 2.5 x ULN ANC &gt; 1.5 Platlets &gt; 100,000 Patient willing able use cell phone Written , voluntary inform consent Patient significant history noncompliance medical regimen inability grant reliable informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Chronic Myeloid Leukemia</keyword>
</DOC>